Literature DB >> 14302363

THE EXCRETION OF DEXAMPHETAMINE AND ITS DERIVATIVES.

A M ASATOOR, B R GALMAN, J R JOHNSON, M D MILNE.   

Abstract

Entities:  

Keywords:  CHROMATOGRAPHY; DEXTRO AMPHETAMINE; HYDROGEN-ION CONCENTRATION; LIVER FUNCTION; METABOLISM; RATS; TOXICOLOGIC REPORT; URINE

Mesh：

Substances：

Year:  1965        PMID： 14302363      PMCID： PMC1704066          DOI： 10.1111/j.1476-5381.1965.tb02105.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN： 0366-0826


× No keyword cloud information.
  12 in total

1.  Amines in blood and urine in relation to liver disease.

Authors:  A M ASATOOR; D N KERR
Journal:  Clin Chim Acta       Date:  1961-03       Impact factor: 3.786

2.  FATAL AMPHETAMINE POISONING.

Authors:  E G ZALIS; L F PARMLEY
Journal:  Arch Intern Med       Date:  1963-12

3.  The enzymatic deamination of amphetamine (benzedrine).

Authors:  J AXELROD
Journal:  J Biol Chem       Date:  1955-06       Impact factor: 5.157

4.  The phenolic acids of human urine; paper chromatography of phenolic acids.

Authors:  M D ARMSTRONG; K N SHAW; P E WALL
Journal:  J Biol Chem       Date:  1956-01       Impact factor: 5.157

5.  Non-ionic diffusion and the excretion of weak acids and bases.

Authors:  M D MILNE; B H SCRIBNER; M A CRAWFORD
Journal:  Am J Med       Date:  1958-05       Impact factor: 4.965

6.  The importance of ionization in the activity of sympathomimetic amines.

Authors:  G P LEWIS
Journal:  Br J Pharmacol Chemother       Date:  1954-12

7.  Studies in detoxication. 59. The metabolism of alkylbenzenes; the biological reduction of ketones derived from alkylbenzenes.

Authors:  J N SMITH; R H SMITHIES; R T WILLIAMS
Journal:  Biochem J       Date:  1954-05       Impact factor: 3.857

8.  Studies on sympathomimetic amines. II. The biotransformation and physiological disposition of d-amphetamine, d-p-hydroxyamphetamine and d-methamphetamine.

Authors:  J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1954-03       Impact factor: 4.030

9.  The determination of d-amphetamine in body fluids.

Authors:  R E KELLER; W C ELLENBOGEN
Journal:  J Pharmacol Exp Ther       Date:  1952-09       Impact factor: 4.030

10.  The excretion of pethidine and its derivatives.

Authors:  A M ASATOOR; D R LONDON; M D MILNE; M L SIMENHOFF
Journal:  Br J Pharmacol Chemother       Date:  1963-04
View more
  9 in total

1.  Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment.

Authors:  D P Van Kammen; D L Murphy
Journal:  Psychopharmacologia       Date:  1975-11-21

2.  Critical flicker frequency and centrally-acting drugs.

Authors:  P Turner
Journal:  Br J Ophthalmol       Date:  1968-03       Impact factor: 4.638

Review 3.  Diuretics. II. Clinical considerations.

Authors:  J L Anderton; P Kincaid-Smith
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 4.  The interaction of drugs, with particular reference to anaesthetic practice.

Authors:  L C Jenkins
Journal:  Can Anaesth Soc J       Date:  1968-03

5.  The mechanism of the augmentation of responses to indirectly acting sympathomimetic amines by monoamine oxidase inhibitors.

Authors:  M J Rand; F R Trinker
Journal:  Br J Pharmacol Chemother       Date:  1968-06

6.  Influence of urinary pH on the degree and duration of action of amphetamine on the critical flicker fusion frequency in man.

Authors:  J V Smart; P Turner
Journal:  Br J Pharmacol Chemother       Date:  1966-02

7.  Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.

Authors:  Suma M Krishnan; Michael Pennick; Jeffrey G Stark
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

8.  The metabolic fate of amphetamine in man and other species.

Authors:  L G Dring; R L Smith; R T Williams
Journal:  Biochem J       Date:  1970-02       Impact factor: 3.857

9.  Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.

Authors:  Katarina Ilic; Alan R Kugler; Brian Yan; Nora McNamara
Journal:  CNS Drugs       Date:  2021-11-26       Impact factor: 5.749
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.